MSD Pharma likely to participate in global tender for procurement of HPV vaccine against cervical cancer

The Union Health Ministry is likely to float a global tender for HPV in April for 16.02 crore doses to be procured by 2026.;

Published On 2023-02-16 05:58 GMT | Update On 2024-02-13 19:20 GMT

New Delhi: MSD Pharmaceuticals is willing to participate in a global tender that the Union Health Ministry is likely to float in April to procure HPV vaccine against cervical cancer for immunisation of girls aged 9 to 14. MSD Pharmaceuticals Private Limited, a wholly-owned subsidiary of Merck Sharp and Dohme (known as Merck and Co Inc in the US and Canada), sells its HPV vaccine Gardasil 4 (quadrivalent vaccine) in India. It is currently priced at Rs 3,927 per dose.

The company launched its first gender-neutral HPV vaccine, Gardasil 9, in the country in 2021. The nine-valent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52 and 58 ) vaccine is currently priced in India at Rs 10,850 per dose.

"With HPV affecting both genders, the launch of advanced Gardasil 9 vaccine demonstrates our commitment towards bringing a gender-neutral HPV vaccine to our country that addresses certain HPV related diseases among Indian girls, women and boys, and MSD will continue to promote preventive healthcare in India," the company told PTI in response to a question.

The Union Health Ministry intends to begin administering the HPV vaccine against cervical cancer under the universal immunisation programme in a phased manner from June.

It is likely to float a global tender for HPV in April for 16.02 crore doses to be procured by 2026.

"We would be keen to work on the immunisation programme if the Government of India floated a global tender. We are also working with several state governments in other key areas such as maternal health, oncology and can similarly collaborate to provide HPV vaccines under wider roll-out plans," the company said in response to a question.

On how important the Indian market is for the cervical cancer vaccine, MSD said currently there is less than one percent penetration for HPV vaccination in the target cohort. There is indeed an urgent need for HPV vaccination awareness in India.

"In India, Gardasil 4 is approved for women between the age of 9-45 years. It means we have around 300 million women in India who need protection from HPV related cancers and MSD is taking efforts in this direction. The government is also taking a lot of efforts in educating the general population around prevention of cervical cancer," it said.

The Serum Institute's made-in-India vaccine against cervical cancer, CERVAVAC, was launched last month.

Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), wrote a letter to the Health Ministry recently, saying its first indigenous HPV vaccine will be available in the private market at an MRP of Rs 2,000 per dose, it has been learnt. CERVAVAC will be available in two-dose glass vial presentation.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

MSD Pharma likely to participate in global tender for procurement of HPV vaccine against cervical cancer

The Union Health Ministry is likely to float a global tender for HPV in April for 16.02 crore doses to be procured by 2026.;

Similar News

Four senior employees of Medley Pharma booked over Palghar gas leak

Kotapally raid: Large cache of medicines bound for Maharashtra confiscated

Ravenbhel's Bilastine, Montelukast FDC Under Review, CDSCO Panel Seeks Pediatric Expert Opinion

From Breakthrough to Backlash: Novo Nordisk's Ozempic Faces USD 2 Billion Lawsuit

Aurobindo Pharma Clarifies Zentiva Acquisition Reports 'Premature', No Binding Pact Finalised

CDSCO Digitisation Cuts Post-Approval Change Timelines in CGTs from 218 to 98 Days: DCGI

PLI scheme brings down cost of rare disease treatment from crores to lakhs

Aurobindo Pharma in lead to acquire Zentiva for US 5.5 billion: ET Report